ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0773

Janus Kinase (JAK) Inhibition with Baricitinib: Dosing and Patient-Reported Outcomes in Refractory Juvenile Dermatomyositis

Hanna Kim1, Ly-Lan Bergeron2, Samantha Dill2, MIchelle O'Brien2, Xiaobai Li3, Jomy George3, April Brundidge2, Michelle Millwood2, Lisa Rider4 and Robert Colbert5, 1Juvenile Myositis Pathogenesis and Therapeutics Unit, NIAMS, National Institutes of Health, Bethesda, MD, 2Office of Clinical Director, NIAMS, National Institutes of Health, Bethesda, MD, 3Clinical Center, National Institutes of Health, Bethesda, MD, 4NIEHS, NIH, Garrett Park, MD, 5NIH/NIAMS, Bethesda, MD

Meeting: ACR Convergence 2021

Keywords: dermatomyositis, Intervention, Patient reported outcomes, Pediatric rheumatology, quality of life

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 7, 2021

Session Title: Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications. In a compassionate use program, we assessed baricitinib (JAK 1/2 inhibitor) in active, refractory JDM and recently demonstrated efficacy by clinically relevant improvements in validated disease activity assessments and decreased IFN markers by 24 weeks.(1) Here we report patient-reported outcomes (PRO) and dosing with extended follow-up.

Methods: Baricitinib was dosed based on weight and renal function, with options to adjust dose based on established dosing and pharmacokinetics in pediatric interferonopathies.(2) One of the primary outcomes was reduction in symptom daily diary score (DDS) of weakness, fatigue, musculoskeletal pain, and rash. Each symptom was graded based on impact from 0 (no impact, not present) to 4 (maximal impact, highest grade), with symptom categories averaged for diary scores. DDS were collected for at least 2 weeks prior to starting investigational drug and then daily throughout the program. Other PROs included Patient/Parent Global Assessment (PtGA) by visual analog scale, (Childhood) Health Assessment Questionnaire (C/HAQ), and Childhood Health Questionnaire–Physical Summary Score (CHQ-PhS). Linear mixed models were used to compare measures to baseline. Safety and tolerability were assessed.

Results: Four patients with JDM (5.8-20.7 years old) were enrolled (NCT01724580), with at least 72 weeks of follow-up data collected. Patient diaries were collected for a total of 2167 days, with 2163 (99.8%) days of diary entries completed. At 72 weeks, DDS changed from a mean of 2.0/4.0 (range 1.1-2.3) to 0.4 (0.2-0.7; 68-83% decrease, p< 0.01) (Fig 1A). PtGA decreased from a mean of 5.9/10.0 (4.3-9.0) to 1.7 (0.4-4.7; 48-92% decrease, p< 0.01) (Fig 1B). C/HAQ decreased from mean 1.13/3.0 (range 0.0-2.13) to 0.66 (0.0-1.63, 0-100% decrease), indicating less disability (Fig 1C). CHQ-PhS (n=3) increased from mean 34.9/100 (29.1-45.0) to 48.0 (43.0-50.7; 13-65% increase), indicating improved physical function-related quality of life (Fig 1D). Patients were started on baricitinib 4-8mg PO per day divided BID or TID, and at last time point were on 5-12 mg/day divided BID. Dose adjustments were made based on renal function, safety laboratories, and/or efficacy in three patients. Baricitinib was generally well tolerated. There were no serious adverse events (AEs). Infections were the most common AE; Most common infection was upper respiratory infection. No AEs required holding/discontinuing baricitinib.

Conclusion: Patient-reported outcome data using baricitinib in four patients with refractory JDM supports shows continued improvement in symptoms with less disability and better physical function-related quality of life. Minor baricitinib dosing adjustments within the dosing range for pediatric interferonopathies were generally well tolerated.

Disclosures: Baricitinib provided by Eli Lilly & Company, expanded access program sponsor. Other support: IRP of NIH, NIAMS, NIEHS, CC.

References:
1. Kim H et al, Ann Rheum Dis, 2020
2. Kim H et al, Clin Pharmacol Ther, 2018


Disclosures: H. Kim, Eli Lilly and Company, 12, Provide Drug; L. Bergeron, None; S. Dill, None; M. O'Brien, None; X. Li, None; J. George, None; A. Brundidge, None; M. Millwood, None; L. Rider, Eli Lilly and Company, 12, Drug, CureJM, 1, Bristol Meyer Squibb, 5, Hope Pharmaceuticals, 5; R. Colbert, Eli Lilly and Company, 12, Provide Drug.

To cite this abstract in AMA style:

Kim H, Bergeron L, Dill S, O'Brien M, Li X, George J, Brundidge A, Millwood M, Rider L, Colbert R. Janus Kinase (JAK) Inhibition with Baricitinib: Dosing and Patient-Reported Outcomes in Refractory Juvenile Dermatomyositis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/janus-kinase-jak-inhibition-with-baricitinib-dosing-and-patient-reported-outcomes-in-refractory-juvenile-dermatomyositis/. Accessed January 28, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/janus-kinase-jak-inhibition-with-baricitinib-dosing-and-patient-reported-outcomes-in-refractory-juvenile-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences